Table 3.

Performance of first‐line platinum/etoposide in select randomized trials

Study design	No. of sub. in EP/EC	ORR (%)	mPFS (m)	mOS (m)	References
EP vs. IP	110	48 vs. 44	4.6 vs. 4.1	10.2 vs. 9.3	Hanna et al. (2006)
EP vs. ACE	141	77 vs. 72	NR	7.5 vs. 8.3	Baka et al. (2008)
EC vs. carbo/pemetrexed	455	52 vs. 31	5.4 vs. 3.8	10.6 vs. 8.1	Socinski et al. (2009)
EC or EP ± bevacizumab	50	48 vs. 58	4.4 vs. 5.5	10.9 vs. 9.4	Spigel et al. (2011)
EC or EP ± ipilimumab	476	62 vs. 62	4.4 vs. 4.6	10.9 vs. 11.0	Reck et al. (2016)
EC ± palifosfamide	94	NR	NR	10.4 vs. 10.0	Jalal et al. (2017)
EP ± bevacizumab	103	55 vs. 58	5.7 vs. 6.7	8.9 vs. 9.8	Tiseo et al. (2017)

Abbreviations: EP, platinum/etoposide; EC, carboplatin/etoposide; mOS, median overall survival; mPFS, median progression free survival; ORR, overall response rate.